Population Pharmacokinetics and Pharmacodynamics of Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction-Reference-Cited by-同舟云学术

Population Pharmacokinetics and Pharmacodynamics of Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction

Published:2021-06-04 Issue:11 Volume:60 Page:1407-1421
ISSN:0312-5963
Container-title:Clinical Pharmacokinetics
language:en
Short-container-title:Clin Pharmacokinet

Author:

Ruehs Hauke^ORCID,Klein Dagmar,Frei Matthias,Grevel Joachim,Austin Rupert,Becker Corina,Roessig Lothar,Pieske Burkert,Garmann Dirk,Meyer Michaela^ORCID

Funder

Bayer AG

Merck Sharp and Dohme

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology

Link

https://link.springer.com/content/pdf/10.1007/s40262-021-01024-y.pdf

Reference40 articles.

1. Benjamin EJ, Virani SS, Callaway CW, Chamberlain AM, Chang AR, Cheng S, et al. Heart disease and stroke statistics: 2018 update A report from the American Heart Association. Circulation. 2018;137(12):e67-492.

2. Cook C, Cole G, Asaria P, Jabbour R, Francis DP. The annual global economic burden of heart failure. Int J Cardiol. 2014;171(3):368–76.

3. Vos T, Abajobir AA, Abate KH, Abbafati C, Abbas KM, Abd-Allah F, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390(10100):1211–59.

4. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, et al. Eur J Heart Fail. 2016;18(8):891–975.

5. Butler J, Yang M, Manzi MA, Hess GP, Patel MJ, Rhodes T, et al. Clinical course of patients with worsening heart failure with reduced ejection fraction. J Am Coll Cardiol. 2019;73(8):935–44.

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Who Can Receive Clinical Benefit from Mid-Term Vericiguat Add-on Therapy Among Patients with Systolic Heart Failure Receiving Quadruple Medical Therapy?;International Heart Journal;2024-07-31

2. New Therapeutics for Heart Failure Worsening: Focus on Vericiguat;Journal of Clinical Medicine;2024-07-19

3. Clinical Pharmacokinetic and Pharmacodynamic Profile of Vericiguat;Clinical Pharmacokinetics;2024-06

4. The Evolving Role of Vericiguat in Patients With Chronic Heart Failure;Cureus;2023-12-01

5. Vericiguat, a novel sGC stimulator: Mechanism of action, clinical, and translational science;Clinical and Translational Science;2023-11-23